

Dear editor,

Here is point-by-point response to each of the issues raised in the peer review report.

Reviewer #1:

Scientific Quality: Grade C (Good)

Language Quality: Grade A (Priority publishing)

Conclusion: Minor revision

Specific Comments to Authors: This paper is a very rare case report of three hematological malignancies simultaneously in the same patient. An autopsy was not performed, and it seems that the pathological condition was almost analyzed with the limited number of specimens taken before his death. I find it hard to believe that there are 'tumor cells with both MDS clones and B-LPD (LPL/WM) clones' in the bone marrow, but the authors' data make me think so. On the other hand, DLBCL with chest wall and multiple nodal lesions (pathological confirmation was not obtained) was also observed. This aggressive triple expressor DLBCL should also be analyzed by FISH for BCL-2, BCL-6, and c-myc, but the specimen was too small to be possible.

Answer:

Thank you for your comments. Exactly, the triple hit DLBCL should have been analyzed by FISH, but the specimen was too small to be done.

Furthermore, I must say that the possibility that this DLBCL was generated by transformation of B-LPD (LPL/WM) is negative based on the authors' data (that is, it was a different clone). In addition, I think that it is better to add the notation 'triple expressor'.

Answer:

Thank you for your advice. The sentence "The positive expression of BCL-2, BCL-6, and c-MYC suggested that DLBCL was a 'triple expressor' type." has been added.

The above is my review, and I agree with the authors' thinking on this case essentially. I would only suggest that you rewrite the first half of the introduction. 'Only few cases who developed DLBCL after AML chemotherapy [1, 2], or who developed AML secondary to the DLBCL treatment [3], were reported.' In particular, the latter has been experienced

frequently (2 cases in the past year in our department), and it is not worth reporting it in papers, so the number of reports is small. Readers may have doubts that the whole paper is shady with this unnecessary sentence at the beginning of this precious report. It is a topic that is not directly related to the content of the paper, so I think it can be deleted.

Answer:

Thank you for your advice. The sentence “or who developed AML secondary to the DLBCL treatment [3], were reported” has been deleted.

4 LANGUAGE POLISHING REQUIREMENTS FOR REVISED MANUSCRIPTS SUBMITTED BY AUTHORS WHO ARE NON-NATIVE SPEAKERS OF ENGLISH

As the revision process results in changes to the content of the manuscript, language problems may exist in the revised manuscript. Thus, it is necessary to perform further language polishing that will ensure all grammatical, syntactical, formatting and other related errors be resolved, so that the revised manuscript will meet the publication requirement (Grade A).

Authors are requested to send their revised manuscript to a professional English language editing company or a native English-speaking expert to polish the manuscript further. When the authors submit the subsequent polished manuscript to us, they must provide a new language certificate along with the manuscript.

Once this step is completed, the manuscript will be quickly accepted and published online. Please visit the following website for the professional English language editing companies we recommend: <https://www.wjgnet.com/bpg/gerinfo/240>.

Answer:

The revised manuscript has been sent to a professional English language editing company for further language polishing. The new language certificate has been provided.

5 ABBREVIATIONS

In general, do not use non-standard abbreviations, unless they appear at least two times in the text preceding the first usage/ definition. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, and mAb, do not need to be defined and can be used directly.

The basic rules on abbreviations are provided here:

(1) Title: Abbreviations are not permitted. Please spell out any abbreviation in the title.

(2) Running title: Abbreviations are permitted. Also, please shorten the running title to no more than 6 words.

(3) Abstract: Abbreviations must be defined upon first appearance in the Abstract. Example 1: Hepatocellular carcinoma (HCC). Example 2: *Helicobacter pylori* (*H. pylori*).

(4) Key Words: Abbreviations must be defined upon first appearance in the Key Words.

(5) Core Tip: Abbreviations must be defined upon first appearance in the Core Tip. Example 1: Hepatocellular carcinoma (HCC). Example 2: *Helicobacter pylori* (*H. pylori*)

(6) Main Text: Abbreviations must be defined upon first appearance in the Main Text. Example 1: Hepatocellular carcinoma (HCC). Example 2: *Helicobacter pylori* (*H. pylori*)

(7) Article Highlights: Abbreviations must be defined upon first appearance in the Article Highlights. Example 1: Hepatocellular carcinoma (HCC).

Example 2: *Helicobacter pylori* (*H. pylori*)

(8) Figures: Abbreviations are not allowed in the Figure title. For the Figure Legend text, abbreviations are allowed but must be defined upon first appearance in the text. Example 1: A: Hepatocellular carcinoma (HCC) biopsy sample; B: HCC-adjacent tissue sample. For any abbreviation that appears in the Figure itself but is not included in the Figure Legend textual description, it will be defined (separated by semicolons) at the end of the figure legend. Example 2: BMI: Body mass index; US: Ultrasound.

(9) Tables: Abbreviations are not allowed in the Table title. For the Table itself, please verify all abbreviations used in tables are defined (separated by

semicolons) directly underneath the table. Example 1: BMI: Body mass index; US: Ultrasound.

Answer:

The abbreviation in the title has been spelt out. Abbreviations have been defined upon first appearance in the Abstract, Key Words, Core Tip and Main Text. Abbreviations did not show in the Figure title and Table title. The abbreviations have been defined upon first appearance in the Figure Legend Text and Table.

6 EDITORIAL OFFICE'S COMMENTS

Authors must revise the manuscript according to the Editorial Office's comments and suggestions, which are listed below:

(1) Science editor:

The manuscript has been peer-reviewed, and it's ready for the first decision.

(2) Company editor-in-chief:

I have reviewed the Peer-Review Report, the full text of the manuscript, and the relevant ethics documents, all of which have met the basic publishing requirements of the World Journal of Clinical Cases, and the manuscript is conditionally accepted. I have sent the manuscript to the author(s) for its revision according to the Peer-Review Report, Editorial Office's comments and the Criteria for Manuscript Revision by Authors. Before its final acceptance, the author(s) must provide the Signed Consent for Treatment Form(s) or Document(s) (患者治疗/手术同意书或病例首页).

Answer:

The Signed Consent for Treatment Form(s) or Document(s) has been submitted.

Before final acceptance, uniform presentation should be used for figures showing the same or similar contents; for example, "Figure 1 Pathological changes of atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...". Please provide the original figure documents. Please prepare and arrange the figures using PowerPoint to ensure that all graphs or arrows or text portions can be reprocessed by the editor.

Answer:

The uniform presentation has been used for all figures. The original figure documents have been provided as the file type of PowerPoint which can be reprocessed by editor.

In order to respect and protect the author's intellectual property rights and prevent others from misappropriating figures without the author's authorization or abusing figures without indicating the source, we will indicate the author's copyright for figures originally generated by the author, and if the author has used a figure published elsewhere or that is copyrighted, the author needs to be authorized by the previous publisher or the copyright holder and/or indicate the reference source and copyrights. Please check and confirm whether the figures are original (i.e. generated de novo by the author(s) for this paper). If the picture is 'original', the author needs to add the following copyright information to the bottom right-hand side of the picture in PowerPoint (PPT): Copyright ©The Author(s) 2023.

Answer:

The pictures are original. The words "Copyright ©The Author(s) 2023" has been added to the bottom right-hand side of the picture in PowerPoint (PPT).

Authors are required to provide standard three-line tables, that is, only the top line, bottom line, and column line are displayed, while other table lines are hidden. The contents of each cell in the table should conform to the editing specifications, and the lines of each row or column of the table should be aligned. Do not use carriage returns or spaces to replace lines or vertical lines and do not segment cell content. Please upload the approved grant application form(s) or funding agency copy of any approval document(s).

Answer:

The Table was three-line table. The approved grant application form has been uploaded.